Table 1. Mean kinetic rate and affinity constants determined from SPR experiments on the LSA instrument equipped with a flat sensor chip (CMD-P).

MAbs are affinity-ranked, with upper limits reported for k_d-limited mAbs (in bold)–see Materials and Methods. All data were collected in parallel on a single array, except for mAb01 and mAb35, which were analyzed in a separate experiment. Binding to PD-1 was not observed for mAb24 during this portion of the study, thus no data is reported for this interaction.

mAb ID	Analog of indicated INN	N	Mean ka (M-1s-1) x105	ka Std. Dev. x105	Mean kd (s-1) x10-4	kd Std. Dev. x10-4	Mean KD (nM)	KD Std. Dev.
mAb03	tislelizumab	12	4.3	0.4	<0.43	0	<0.099	0.008
mAb20		12	3.4	0.2	<0.43	0	<0.127	0.009
mAb21	sintilimab	12	3.3	0.2	<0.43	0	<0.13	0.01
mAb19	sasanlimab	12	2.5	0.3	<0.43	0	<0.17	0.02
mAb18		12	2.2	0.1	<0.43	0	<0.19	0.01
mAb28		8	2.1	0.1	<0.43	0	<0.20	0.01
mAb06		12	4.3	0.4	1.1	0.3	0.26	0.07
mAb34		12	0.7	0.1	<0.43	0	<0.59	0.05
mAb04	retifanlimab	12	5.8	0.5	3.9	0.6	0.7	0.1
mAb23	cemiplimab	12	1.9	0.2	2.8	0.4	1.5	0.3
mAb16	dostarlimab	12	2.4	0.1	3.9	0.2	1.6	0.1
mAb31		8	2.6	0.1	4.1	0.3	1.6	0.1
mAb32		8	7.5	0.3	14	1.2	1.9	0.2
mAb01		2	1.4	0.1	2.9	0.2	2.1	0.2
mAb27		8	6.8	0.3	17	2	2.4	0.3
mAb26		8	7.4	0.3	18	1	2.5	0.2
mAb05		12	0.5	0.0	1.7	0.3	3.1	0.5
mAb09		12	0.13	0.01	<0.43	0	<3.2	0.2
mAb29		8	1.5	0.1	4.8	0.2	3.2	0.2
mAb13	pembrolizumab	12	6.7	0.8	27	2	3.9	0.5
mAb17	camrelizumab	12	1.8	0.1	7.3	0.6	4.0	0.4
mAb33		4	3.2	0.4	17	3	6	1
mab22	nivolumab	12	3.1	0.3	22	2	7.2	0.8
mAb12		12	2.0	0.2	18	1	9	1
mAb10		12	0.9	0.1	8.7	0.5	9.4	0.8
mAb08		12	1.2	0.1	15	2	12	2
mAb15	balstilimab	12	2.4	0.1	29	2	12	1
mAb07		12	0.50	0.03	26	1	52	4
mAb02		12	0.57	0.02	38	2	67	4
mAb35		8	4.8	0.2	460	20	96	6
mAb14		12	0.29	0.01	40	4	136	14
mAb11		12	0.8	0.1	231	24	308	44
mAb25		8	1.6	0.2	691	102	424	89